Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET
Rhea-AI Summary
Harvard Bioscience (Nasdaq: HBIO) will release its financial results for the quarter ended June 30, 2026 before the market opens on August 11, 2026. The company will host an earnings conference call at 8:00 a.m. Eastern Time the same day to discuss the results.
Analysts who wish to ask questions must register in advance to receive dial-in details and a unique PIN. Other participants can access an audio-only webcast via the events and presentations section of the investor website. The earnings release, financial information and slide presentation will be available in the Investor Relations section of Harvard Bioscience’s website.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | Q1 earnings results | Negative | -20.9% | Revenue declined despite improved gross margin and a sharply narrower net loss. |
| May 07 | Investor conference participation | Neutral | -6.2% | Management announced participation in two virtual investor events during May. |
| Apr 28 | Q1 earnings scheduling | Neutral | -5.6% | The company scheduled its first-quarter results release and conference call. |
| Mar 12 | FY25 earnings results | Neutral | -2.6% | Full-year results included guidance, margin metrics, and a substantial goodwill impairment. |
| Mar 06 | Reverse stock split | Negative | -11.6% | The company announced a one-for-ten reverse stock split effective March 13. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
HBIO declined after all five listed news events, including earnings releases and conference-related announcements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOLLISTON, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2026, before the market opens on August 11, 2026, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.
Analysts who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.
Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here.
Financial information presented on the call, including the earnings release and a related slide presentation, will be available on the Investor Relations section of Harvard Bioscience’s website.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Company Contact:
Mark Frost
Chief Financial Officer
(508) 893-3120
investors@harvardbioscience.com
